In the news | 7th October 2026
Regulatoriske søknader til CMC: Hvorfor kontinuitet i kunnskapen er viktig
The biopharmaceutical industry has made enormous progress in digitizing scientific and manufacturing data. Yet for many organizations, the greatest risk to successful CMC regulatory submissions is no longer data availability, but knowledge continuity.
Every development program generates thousands of decisions. Why was a specification changed? What evidence supported a process adjustment? What assumptions influenced a particular development path? While the data may still exist, the scientific rationale behind those decisions is often fragmented across documents, emails, spreadsheets, presentations and individual expertise.
This challenge becomes increasingly significant as products advance toward regulatory submission. Teams change, projects are transferred between functions and sites, and key contributors move on. Without a clear record of decision lineage, organizations can find themselves reconstructing historical context that was once readily understood but was never formally captured.
A modern digital strategy must therefore do more than store data. It must preserve the relationships between data, decisions, supporting evidence and scientific reasoning to create a durable record of product knowledge throughout the development lifecycle.
In a recent SelectScience interview, industry experts explore why knowledge continuity is emerging as a strategic priority for biopharma organizations and discuss practical approaches to preserving decision lineage, supporting technology transfer and strengthening readiness for CMC regulatory submissions.
Om forfatterne
Ken Forman, Lead Product Manager, IDBS (left) and Mark Buswell, Director of AMB Engineering and Technology and a former Vice President at GSK (right).